Stock 6996 ANTENGENE CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Antengene Corporation Limited

Equities

6996

KYG039571008

Delayed Hong Kong S.E.
Other stock markets
 02:21:26 2024-04-19 am EDT 		5-day change 1st Jan Change
0.83 HKD -3.49% Intraday chart for Antengene Corporation Limited -12.63% -58.50%
Mar. 22 Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 20 Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study CI

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • With an enterprise value anticipated at 2.59 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ANTENGENE CORPORATION LIMITED Stock Antengene Corporation Limited
-58.50% 74.12M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.07B
B+
ARGENX SE Stock argenx SE
-0.44% 21.66B
B
BIONTECH SE Stock BioNTech SE
-18.35% 20.77B
B+
GENMAB A/S Stock Genmab A/S
-7.45% 18.53B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.91B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.79B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.33B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 10.94B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6996 Stock
  4. Ratings Antengene Corporation Limited